When people think of life-threatening infections, bacterial and viral diseases typically come to mind. However, for infectious disease experts like Peter Chin-Hong, invasive fungal infections are emerging as some of the deadliest threats in hospitals and clinics today.
Chin-Hong, associate dean and professor of medicine at the University of California, San Francisco, has witnessed this firsthand. His cases include a 29-year-old marathon runner from California’s Central Valley whose heart lining was overtaken by Coccidioides, a soil-based fungus; a lung transplant patient coughing up mold nodules after discontinuing antifungal drugs; and a 45-year-old woman with uncontrolled diabetes whose face and brain were ravaged by a black fungus, leading to her death despite aggressive treatment.
“These invasive fungal infections aren’t rare anymore,” Chin-Hong warns. “We’re seeing them daily.”
Once considered uncommon or opportunistic, deadly fungal infections are surging at an alarming rate—appearing in unexpected patients and regions. Climate change is expanding the range of fungi, while medical advancements like organ transplants, chemotherapy, and intensive care leave more people immunocompromised. Even widespread conditions like diabetes heighten the risk of severe fungal diseases.
Globally, an estimated 6.5 million people develop invasive fungal infections annually, with 2.5 million fatalities directly attributed to them—double the death toll of tuberculosis. Many of these deaths occur in individuals with advanced HIV, and experts fear that cuts to global HIV/AIDS funding could worsen the fungal infection crisis, particularly in low-resource areas lacking diagnostic tools and antifungal treatments.
Compounding the issue is the rise of drug-resistant fungal infections, such as Candida auris, a yeast first identified in 2009 that’s now causing lethal outbreaks in hospitals and care facilities. With resistance growing and new antifungal drug development lagging, the situation is dire.
The Escalating Fungal Infection Crisis
On Tuesday, the World Health Organization (WHO) highlighted critical global shortcomings in diagnosing and treating fungal infections. The pipeline for new antifungal medications is alarmingly thin, with only four approved in the past decade and just nine in clinical development—three of which are in the final stages.
“We’re unlikely to see many new antifungal drugs approved in the next decade,” said Valeria Gigante, head of WHO’s antimicrobial resistance division in Geneva. Over half of these candidates lack innovative mechanisms to tackle rising resistance. “We urgently need novel ways to combat deadly fungi,” she emphasized, noting that only three target the most dangerous pathogens.
Fungal threats remain dangerously underrecognized, according to Justin Beardsley, an infectious disease expert at the University of Sydney. “Fungal infections fly under the radar,” he said. “They’re uncontrolled because we’re not prioritizing solutions.”
Beardsley also raised concerns about agricultural antifungal use, where new compounds are deployed faster to protect crops from diseases like powdery mildew than to treat humans. “This accelerates resistance, undermining new drugs before they even reach patients,” he warned.
Diagnostics are another weak link. The WHO notes that even when tests exist to detect deadly fungi, they’re scarce in low- and middle-income countries, requiring advanced labs and skilled staff. Systems to identify fungal infections and assess drug resistance also trail far behind those for bacteria.
The Unseen Danger of Fungal Infections
Unlike bacteria or viruses, fungal infections rarely spread between people. Instead, they originate from environmental sources—moldy soil, rotting plants, or airborne spores that can travel continents, making them nearly impossible to contain.
This unpredictability complicates protection for vulnerable patients. Chin-Hong often prescribes preventive antifungal drugs to high-risk groups, like lung or stem cell transplant recipients, but these medications don’t cover all fungi. Mucormycosis, a rare yet aggressive infection, is particularly challenging.
“Mucormycosis is the most terrifying fungal infection we face,” Chin-Hong said. With an 87% mortality rate in the lungs and 50% when it spreads to the brain via the sinuses, it destroys tissue and blocks blood flow, rendering drugs ineffective. “Surgery is often the only option—sometimes removing an eye or other areas—but in the lungs, resection is rarely feasible,” he explained.
Even when antifungal treatments work, they’re less effective in immunocompromised patients—the very group most at risk. “We have drugs now,” Chin-Hong said, “but our options are dwindling fast.”
Why This Matters for Global Health
The surge in invasive fungal infections, fueled by climate change, medical advancements, and drug resistance, demands urgent attention. With millions of lives at stake and limited tools to fight back, experts are sounding the alarm on this escalating public health crisis. Enhanced diagnostics, innovative antifungal drugs, and global awareness are critical to curbing this unseen yet deadly threat.
No comments:
Post a Comment